BR0010984A - Matrizes porosas de medicamento e processos para fabricação das mesmas - Google Patents
Matrizes porosas de medicamento e processos para fabricação das mesmasInfo
- Publication number
- BR0010984A BR0010984A BR0010984-3A BR0010984A BR0010984A BR 0010984 A BR0010984 A BR 0010984A BR 0010984 A BR0010984 A BR 0010984A BR 0010984 A BR0010984 A BR 0010984A
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- porous matrix
- forming agent
- pore forming
- volatile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Epoxy Compounds (AREA)
Abstract
"MATRIZES POROSAS DE MEDICAMENTO E PROCESSOS PARA FABRICAçãO DAS MESMAS". Medicamentos, especialmente medicamentos de solubilidade aquosa baixa são providos em uma forma de matriz porosa, preferivelmente micropartículas, o que melhora a dissolução do medicamento em um meio aquoso. As matrizes de medicamento preferivelmente são feitas usando um processo que inclui (i) dissolução de um medicamento, preferivelmente um medicamento possuindo uma solubilidade aquosa baixa, em um solvente volátil, para formar uma solução de medicamento, (ii) combinação de pelo menos um agente de formação de poro com a solução de medicamento para formar uma emulsão, suspensão ou segunda solução e (iii) remoção do solvente volátil e agente de formação de poro da emulsão, suspensão ou segunda solução para render a matriz porosa do medicamento. O agente de formação de poro pode ser tanto um líquido volátil que é imiscível com o solvente de medicamento ou um composto sólido volátil, preferivelmente um sal volátil. Em uma concretização preferida, a secagem por aspersão é usada para remover os solventes e o agente de formação de poro. A matriz porosa resultante possui uma razão mais rápida de dissolução, seguindo administração a um paciente, conforme comparado às formas de matriz não porosa do medicamento. Em uma concretização preferida, as micropartículas da matriz de medicamento porosa são reconstituídas com um meio aquoso e administradas parenteralmente ou processadas usando técnica padrão em comprimidos ou cápsulas para administração oral. Paclitaxel ou docetaxel podem ser providos em forma de matriz porosa, o que permite que o medicamento seja formulado sem agentes de solubilização e administrado como um bolo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13632399P | 1999-05-27 | 1999-05-27 | |
US15865999P | 1999-10-08 | 1999-10-08 | |
US09/433,486 US6395300B1 (en) | 1999-05-27 | 1999-11-04 | Porous drug matrices and methods of manufacture thereof |
US18631000P | 2000-03-02 | 2000-03-02 | |
PCT/US2000/014578 WO2000072827A2 (en) | 1999-05-27 | 2000-05-25 | Porous drug matrices and methods of manufacture thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0010984A true BR0010984A (pt) | 2002-04-30 |
Family
ID=27495210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0010984-3A BR0010984A (pt) | 1999-05-27 | 2000-05-25 | Matrizes porosas de medicamento e processos para fabricação das mesmas |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1180020B2 (pt) |
JP (1) | JP4722295B2 (pt) |
KR (2) | KR100752000B1 (pt) |
CN (1) | CN1240373C (pt) |
AT (1) | ATE312601T1 (pt) |
AU (1) | AU768022B2 (pt) |
BR (1) | BR0010984A (pt) |
CA (1) | CA2371836C (pt) |
DE (1) | DE60024811T3 (pt) |
DK (1) | DK1180020T4 (pt) |
ES (1) | ES2250141T5 (pt) |
HK (2) | HK1048956B (pt) |
IL (2) | IL146659A0 (pt) |
MX (1) | MXPA01012106A (pt) |
NO (1) | NO323761B1 (pt) |
NZ (1) | NZ516083A (pt) |
TW (1) | TWI274589B (pt) |
WO (1) | WO2000072827A2 (pt) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6342533B1 (en) | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
CZ20013607A3 (cs) | 1999-04-06 | 2002-06-12 | Sepracor Inc. | Farmaceutický prostředek |
US8771740B2 (en) * | 1999-12-20 | 2014-07-08 | Nicholas J. Kerkhof | Process for producing nanoparticles by spray drying |
MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
US6589557B2 (en) * | 2000-06-15 | 2003-07-08 | Acusphere, Inc. | Porous celecoxib matrices and methods of manufacture thereof |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
DE10059020A1 (de) * | 2000-11-28 | 2002-05-29 | Gruenenthal Gmbh | Parenteral applizierbare Darreichungsformen |
KR100743404B1 (ko) | 2000-12-21 | 2007-07-30 | 넥타르 테라퓨틱스 | 폴리엔 항균제의 폐 전달 |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
NZ539046A (en) * | 2001-01-18 | 2006-11-30 | Pharmacia & Upjohn Co Llc | Chemotherapeutic self-emulsifying microemulsion compositions of paclitaxel with improved oral bioavailability |
JP4220243B2 (ja) † | 2001-02-12 | 2009-02-04 | ワイス | O−デスメチル−ベンラファキシンの新規コハク酸塩 |
WO2002094231A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of analgesics through an inhalation route |
CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
US7105178B2 (en) | 2001-07-17 | 2006-09-12 | Sun Pharmaceutical Industries Limited | Cardiotonic composition |
WO2003041693A1 (en) * | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
US7005138B2 (en) * | 2001-12-21 | 2006-02-28 | Duramed Pharmaceuticals, Inc. | Method of systematically delivering SSRIs |
EP1531798B1 (en) | 2002-03-20 | 2012-06-06 | Civitas Therapeutics, Inc. | Pulmonary delivery for levodopa |
JP4452970B2 (ja) * | 2002-03-27 | 2010-04-21 | 日本臓器製薬株式会社 | ジクロフェナクナトリウム経口製剤 |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8980870B2 (en) | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
CA2500065A1 (en) * | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
EP1610791B1 (en) | 2003-03-31 | 2011-02-23 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of dopamine agonist |
ATE510174T1 (de) | 2003-05-21 | 2011-06-15 | Alexza Pharmaceuticals Inc | Schlag gezündete unabhängige heizeinheit |
GB0401947D0 (en) | 2004-01-28 | 2004-03-03 | Unilever Plc | Porous bodies and method of production thereof |
KR100681660B1 (ko) * | 2004-03-17 | 2007-02-09 | 주식회사종근당 | 방출제어 펠릿의 약제학적 조성물 |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
EP1681056A1 (en) * | 2005-01-14 | 2006-07-19 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for preparing lansoprazole |
WO2007004236A2 (en) * | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
GB0517688D0 (en) * | 2005-08-31 | 2005-10-05 | Cambridge Biostability Ltd | Improvements in the stabilisation of biological materials |
GB0523638D0 (en) | 2005-11-21 | 2005-12-28 | Cambridge Biostability Ltd | Pharmaceutical device for the administration of substances to patients |
AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
EP1976486A1 (en) * | 2006-01-27 | 2008-10-08 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A method of producing porous microparticles |
KR100917809B1 (ko) * | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
ES2594867T3 (es) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Unidad de calentamiento para usar en un dispositivo de administración de fármaco |
NZ580803A (en) | 2007-04-27 | 2012-03-30 | Endo Pharmaceuticals Solutions | Implant device release agents and methods of using same |
PT103743B (pt) * | 2007-05-16 | 2013-01-15 | Hovione Farmaciencia S A | Processo para preparar derivados de 21-disódio fosfato de pregnanos. |
AU2008291930B2 (en) | 2007-08-24 | 2014-04-17 | Slotervaart Participaties Bv | Compositions for the treatment of neoplastic diseases |
GB0716591D0 (en) * | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
CA2701695A1 (en) * | 2007-10-09 | 2009-04-16 | Novartis Ag | Pharmaceutical formulation of valsartan |
KR101024742B1 (ko) * | 2007-12-31 | 2011-03-24 | 주식회사 삼양사 | 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법 |
US9801818B2 (en) | 2007-12-31 | 2017-10-31 | Samyang Biopharmaceuticals Corporation | Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug |
EP2318350A4 (en) * | 2008-07-25 | 2012-11-28 | Alphapharm Pty Ltd | ATOVAQUONE WITH PARTICLE DIAMETER (D90) VARIANT FROM MORE THAN 3 muM TO ABOUT 10 muM |
EP2328555A2 (en) * | 2008-08-22 | 2011-06-08 | Slotervaart Participaties BV | Compositions for the treatment of neoplastic diseases |
US8685458B2 (en) | 2009-03-05 | 2014-04-01 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
WO2010111132A2 (en) | 2009-03-27 | 2010-09-30 | Bend Research, Inc. | Spray-drying process |
EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
WO2012031133A2 (en) | 2010-09-03 | 2012-03-08 | Bench Research, Inc. | Spray-drying apparatus and methods of using the same |
US9248584B2 (en) | 2010-09-24 | 2016-02-02 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
AU2012221704B2 (en) | 2011-02-23 | 2013-12-05 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
CN103301095B (zh) * | 2012-03-13 | 2016-04-13 | 中国科学院上海药物研究所 | 一种用于提高普罗布考口服吸收的多孔复合载药组合物及其制备方法 |
WO2013188926A1 (en) * | 2012-06-22 | 2013-12-27 | The University Of Queensland | Method and composition for delivering a compound through a biological barrier |
EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
HUE061928T2 (hu) | 2014-06-11 | 2023-09-28 | SpecGx LLC | Különbözõ oldódási profillal rendelkezõ porlasztva szárított készítmények és elõállításukhoz szükséges eljárások |
US11364203B2 (en) | 2014-10-31 | 2022-06-21 | Bend Reserch, Inc. | Process for forming active domains dispersed in a matrix |
WO2016100949A2 (en) * | 2014-12-18 | 2016-06-23 | Windgap Medical, Inc. | Method and compositions for dissolving or solubilizing therapeutic agents |
DK3302431T3 (da) | 2015-06-04 | 2020-11-30 | Crititech Inc | Taxanpartikler og anvendelse deraf |
EP3324930A2 (en) | 2015-09-16 | 2018-05-30 | DFB Soria, LLC | Delivery of drug nanoparticles and methods of use thereof |
RU2737934C2 (ru) * | 2016-04-04 | 2020-12-07 | Крититек, Инк. | Способы лечения солидных опухолей |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
KR101965708B1 (ko) * | 2016-08-30 | 2019-04-04 | 이화여자대학교 산학협력단 | 스폰지 유사 구조를 갖는 고분자 미립자 및 이의 제조방법 |
CN110636833B (zh) | 2017-03-15 | 2024-07-09 | Dfb索里亚有限责任公司 | 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法 |
KR20200014279A (ko) | 2017-06-09 | 2020-02-10 | 크리티테크, 인크. | 항신생물 입자의 낭내 주사에 의한 상피낭종의 치료 |
SG10201913400QA (en) | 2017-06-14 | 2020-03-30 | Crititech Inc | Methods for treating lung disorders |
RU2020110399A (ru) | 2017-10-03 | 2021-11-09 | Крититек, Инк. | Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака |
CA3087698A1 (en) | 2018-01-05 | 2019-07-11 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
CN112165949A (zh) | 2018-03-16 | 2021-01-01 | Dfb索里亚有限责任公司 | 使用紫杉烷纳米颗粒治疗宫颈上皮内瘤变(cin)和宫颈癌的局部疗法 |
WO2020159676A1 (en) * | 2019-01-29 | 2020-08-06 | Bayer Healthcare Llc | Topical gel compositions of naproxen |
KR20220044160A (ko) * | 2019-05-10 | 2022-04-06 | 아노메라 아이엔씨. | 다공성 셀룰로스 마이크로입자 및 그의 제조 방법 |
LT4037666T (lt) | 2020-12-08 | 2024-06-10 | Ruminant Biotech Corp Limited | Medžiagų pristatymo gyvūnams prietaisų ir būdų patobulinimai |
CN113081971A (zh) * | 2021-05-14 | 2021-07-09 | 江西中医药大学 | 一种中药多孔核壳型复合粒子粉体及其制备方法和应用 |
CN117538462B (zh) * | 2024-01-10 | 2024-03-26 | 地奥集团成都药业股份有限公司 | 一种氨氯地平贝那普利胶囊有关物质的检测方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1265615A (pt) * | 1970-09-10 | 1972-03-01 | ||
NL7313626A (nl) † | 1973-10-04 | 1975-04-08 | Philips Nv | Gecombineerde inrichting voor het produceren en sselen van warmte met een warmte ver- ende inrichting. |
GB8322007D0 (en) † | 1983-08-16 | 1983-09-21 | Wellcome Found | Pharmaceutical delivery system |
IL82245A (en) * | 1986-04-25 | 1990-07-26 | Basf Ag | Preparation of spray-dried granules of active ingredients |
EP0655237A1 (de) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medizinische Aerosolformulierung |
US5762961A (en) * | 1996-02-09 | 1998-06-09 | Quadrant Holdings Cambridge Ltd. | Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof |
ATE287257T1 (de) * | 1997-01-16 | 2005-02-15 | Massachusetts Inst Technology | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
DE69814428T2 (de) * | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
JP4758525B2 (ja) * | 1998-03-20 | 2011-08-31 | 武田薬品工業株式会社 | 生理活性ポリペプチドの徐放性製剤およびその製造法 |
US6423345B2 (en) * | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
-
2000
- 2000-05-25 KR KR1020017015052A patent/KR100752000B1/ko not_active IP Right Cessation
- 2000-05-25 AT AT00939365T patent/ATE312601T1/de active
- 2000-05-25 IL IL14665900A patent/IL146659A0/xx unknown
- 2000-05-25 ES ES00939365T patent/ES2250141T5/es not_active Expired - Lifetime
- 2000-05-25 KR KR1020077012286A patent/KR100883477B1/ko not_active IP Right Cessation
- 2000-05-25 DK DK00939365T patent/DK1180020T4/da active
- 2000-05-25 EP EP00939365A patent/EP1180020B2/en not_active Expired - Lifetime
- 2000-05-25 MX MXPA01012106A patent/MXPA01012106A/es active IP Right Grant
- 2000-05-25 DE DE60024811T patent/DE60024811T3/de not_active Expired - Lifetime
- 2000-05-25 BR BR0010984-3A patent/BR0010984A/pt not_active IP Right Cessation
- 2000-05-25 AU AU54459/00A patent/AU768022B2/en not_active Ceased
- 2000-05-25 CN CNB008081611A patent/CN1240373C/zh not_active Expired - Fee Related
- 2000-05-25 JP JP2000620939A patent/JP4722295B2/ja not_active Expired - Fee Related
- 2000-05-25 NZ NZ516083A patent/NZ516083A/en not_active IP Right Cessation
- 2000-05-25 CA CA002371836A patent/CA2371836C/en not_active Expired - Fee Related
- 2000-05-25 WO PCT/US2000/014578 patent/WO2000072827A2/en not_active Application Discontinuation
- 2000-05-29 TW TW089110363A patent/TWI274589B/zh not_active IP Right Cessation
-
2001
- 2001-11-21 IL IL146659A patent/IL146659A/en not_active IP Right Cessation
- 2001-11-26 NO NO20015753A patent/NO323761B1/no not_active IP Right Cessation
-
2003
- 2003-02-20 HK HK03101310.8A patent/HK1048956B/zh not_active IP Right Cessation
-
2007
- 2007-02-27 HK HK07102209A patent/HK1094775A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0010984A (pt) | Matrizes porosas de medicamento e processos para fabricação das mesmas | |
RU2420290C2 (ru) | Твердые, пригодные для орального употребления фармацевтические формы применения, содержащие ривароксабан с модифицированным высвобождением | |
JP2000229846A (ja) | 放出制御型剤形 | |
WO2001095877A3 (en) | Porous celecoxib matrices and methods of manufacture thereof | |
SE502590C2 (sv) | Oralt terapeutiskt system innehållande karbamazepin med systemisk verkan, förfarande för framställning och användning därav | |
ATE77946T1 (de) | Injizierbares langwirkendes mikroteilchenpr|parat zur verabreichung entzuendungshemmender mittel. | |
JP2007504270A (ja) | 溶解度増大による治療化合物の浸透性送達 | |
RU2003111950A (ru) | Препарат, содержащий натеглинид | |
EA200000154A1 (ru) | Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях | |
KR960000247A (ko) | 사이클로스포린a 함유 조성물 및 그의 제조방법 | |
Sun et al. | A novel enteric positioning osmotic pump capsule-based controlled release system of sinomenine hydrochloride: In vitro and in vivo evaluation | |
ES2897981T3 (es) | Composición de dos componentes que comprende ácido acetilsalicílico | |
JPS58116414A (ja) | ニカルジピン持続性製剤用球形顆粒およびその製造法 | |
CN101541324B (zh) | 医药组合物 | |
AU2003235156B2 (en) | Solid dispersion composition | |
Xia et al. | Approaches to developing fast release pellets via wet extrusion-spheronization | |
BRPI0810113B1 (pt) | Método para preparação de um extrato seco de pelargonium sidoides e/ou pelargonium reniforme com solubilidade melhorada em solventes fisiologicamente compatíveis | |
ES2310550T3 (es) | Preparacion liquida acuosa de pranoprofeno. | |
CN103948579A (zh) | 左旋多巴/盐酸苄丝肼复方缓释混悬剂及其制备方法 | |
Minocha et al. | SOlubility enhancement of poorly water soluble drugs by various techniques | |
TH78112B (th) | เนื้อสารยารูพรุน และวิธีการของการผลิตของสิ่งเหล่านั้น | |
CN100475203C (zh) | 制备雷公藤内酯醇分子微囊的方法 | |
TH78112A (th) | เนื้อสารยารูพรุน และวิธีการของการผลิตของสิ่งเหล่านั้น | |
CN103251557A (zh) | 一种非洛地平纳米混悬剂及其制备方法 | |
EP0323762B1 (fr) | Nouvelles compositions anti-tussives et leur procédé d'obtention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |